Extended recombinant polypeptides and compositions comprising same
AssigneeAmunix Pharmaceuticals, Inc.
InventorsVolker Schellenberger, Joshua Silverman, Chia-Wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
Claims12
An extended recombinant polypeptide (XTEN) comprising greater than about 400 to about 3000 amino acid residues, wherein the XTEN is characterized in that
- the sum of glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues constitutes more than about 80% of the total amino acid sequence of the XTEN, and
- wherein the XTEN comprises a motif selected from the group consisting of SEQ ID NO:
- 182, SEQ ID NO:
- 183, SEQ ID NO:
- 184, SEQ ID NO:
- 185, SEQ ID NO:
- 191, SEQ ID NO:
- 198, SEQ ID NO:
- 199, SEQ ID NO:
- 200, SEQ ID NO:
- 201, SEQ ID NO:
- 202, SEQ ID NO:
- 203, SEQ ID NO:
- 1715, SEQ ID NO:
- 1716, SEQ ID NO:
- 1717, SEQ ID NO:
- 1718, SEQ ID NO:
- 1719, SEQ ID NO:
- 1720, SEQ ID NO:
- 1721, and SEQ ID NO:
- 1722.
Dependencies are inferred from the claim text.